RT Journal Article
SR Electronic
T1 2022-RA-1178-ESGO Evaluation of prognostic factors in patients with stage IV ovarian cancer
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP A309
OP A309
DO 10.1136/ijgc-2022-ESGO.658
VO 32
IS Suppl 2
A1 Paula Serrano
A1 María Alonso-Espías
A1 Virginia García-Pineda
A1 Myriam Gracia
A1 Jaime Siegrist
A1 María Dolores Diestro
A1 Alicia Hernández
A1 Ignacio Zapardiel
YR 2022
UL http://ijgc.bmj.com/content/32/Suppl_2/A309.1.abstract
AB Introduction/Background The diagnosis of ovarian cancer tends to be late (stages III-IV). The factors that may influence the survival of stage IV patients are not clearly described, especially regarding the initial management of extra-abdominal disease and the possibility of performing surgery despite its existence. This makes it necessary to delve into their knowledge, in order to carry out a more individualized management of these patients. The purpose of this study is to analyze the prognostic factors that may have an effect on overall and disease-free survival of women diagnosed with stage IV ovarian cancer, with special interest on those related to the early management of the disease.Methodology We performed a retrospective analysis including stage IV ovarian cancer patients, treated in Gynecologic Oncology Unit in La Paz University Hospital between 2000 and 2022 (n=110). We analyzed all risk factors that could influence the oncological outcome.Results The correlation between disease-free survival and primary cytoreduction, in absence of residual disease, is demonstrated. No significant differences were observed in terms of overall survival when comparing patients that underwent primary cytoreduction (84 ± 11,1 months) with those who received neoadjuvant chemotherapy (90,7 ± 14,4 months). Statistically significant association was demonstrated between thoracic resection and disease-free survival (p=0,012).Conclusion Age, performance status, initial management of the disease (primary surgery versus neoadjuvant chemotherapy) and complete cytoreduction with no residual disease, which is the greatest prognostic predictor, are the factors that have shown greater association with overall survival.